SBF2-AS1 and TreRNA: novel lncRNA players in triple-negative breast cancer pathogenesis

Mol Biol Rep. 2023 Jul;50(7):6029-6037. doi: 10.1007/s11033-023-08533-y. Epub 2023 Jun 7.

Abstract

Background: Compared to other breast cancer subtypes, triple-negative breast cancer (TNBC) has always been challenging for clinicians due to its aggressive behavior and lack of a specific treatment. There is a confirmed association between invasive features of tumors and increased epithelial-mesenchymal transition (EMT) process, which is consistent with a higher rate of EMT in TNBC.

Methods and results: We investigated the expression of EMT-related genes, SNAI1 and MMP7, and EMT-related lncRNAs, treRNA and SBF2-AS1, in 50 TNBC tumors and 50 non-TNBC tumors to reveal more regulators and effectors involved in TNBC malignancy. In the present study, we showed the overexpression of all the studied genes and lncRNAs in TNBC tumors compared to non-TNBC samples. Moreover, a significant association was observed between MMP7 and treRNA expression levels and larger tumor size. A positive correlation between SNAI1 and lncRNA treRNA expression levels was also detected.

Conclusions: Due to the differential expression and the potential diagnostic power of the studied genes, SBF2-AS1 and treRNA can be proposed as new probable biomarkers and therapeutic targets in TNBC.

Keywords: EMT; MMP7; SBF2-AS1; SNAI1; TreRNA; Triple-negative breast cancer.

MeSH terms

  • Cell Line, Tumor
  • Cell Proliferation / genetics
  • Epithelial-Mesenchymal Transition / genetics
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Matrix Metalloproteinase 7 / genetics
  • MicroRNAs* / genetics
  • RNA, Long Noncoding* / genetics
  • RNA, Long Noncoding* / metabolism
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • RNA, Long Noncoding
  • Matrix Metalloproteinase 7
  • MicroRNAs